Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel

Reyes Maria Martin-Rojas et al.

Summary: Chimeric antigen receptor (CAR) T cell-related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with a poor prognosis and difficult diagnosis. Establishing specific diagnostic criteria is essential, and incorporating multiple CAR T-cell follow-up techniques allows for more precise management of this complication.

CLINICAL CASE REPORTS (2022)

Add to Collection

Article Hematology

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Jordan Gauthier et al.

Summary: The type of CD19 CAR T-cell product independently affects the toxicity and efficacy in patients with relapsed or refractory aggressive B-NHL.

BLOOD (2022)

Add to Collection

Article Hematology

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Wolfgang A. Bethge et al.

Summary: A study conducted in Germany suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting include bridging success, CAR-T product selection, LDH levels, and the absence of prolonged neutropenia and/or severe neurotoxicity.

BLOOD (2022)

Add to Collection

Article Oncology

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States

Richard T. Maziarz et al.

Summary: This study compared the real-world healthcare resource utilization, costs, adverse events, and adverse event treatments associated with two CAR-T therapies, tisagenlecleucel and axicabtagene ciloleucel, for relapsed/refractory diffuse large B-cell lymphoma. The results showed that tisagenlecleucel had shorter inpatient length of stay, lower costs, and similar adverse event rates compared to axicabtagene ciloleucel.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Review Infectious Diseases

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Ibai Los-Arcos et al.

Summary: CAR-T cell therapy is a promising treatment for B-cell malignancies, with two products approved for aggressive B-cell lymphoma and acute lymphoblastic leukemia. Patients receiving CAR-T therapy often develop fever post-infusion, mainly due to cytokine release syndrome.

INFECTION (2021)

Add to Collection

Letter Oncology

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart et al.

LEUKEMIA (2021)

Add to Collection

Letter Oncology

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

Cecilia Carpio et al.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Oncology

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Gloria Iacoboni et al.

Summary: Tisagenlecleucel shows promising efficacy in treating R/R LBCL with a best ORR of 60% and CR of 32%, with a median response duration of 8.9 months. Treatment with tisa-cel in a European SOC setting demonstrates a manageable safety profile and durable complete responses for patients with LBCL.

CANCER MEDICINE (2021)

Add to Collection

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

Add to Collection

Article Hematology

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

Olalekan O. Oluwole et al.

Summary: Prophylactic corticosteroids and earlier intervention with corticosteroids and/or tocilizumab resulted in a reduced rate of severe treatment-related toxicities and high response rates in patients with refractory large B-cell lymphoma. The majority of patients did not experience CRS or NEs within 72 hours of axi-cel treatment. Furthermore, 95% of patients achieved objective responses and 80% achieved complete responses in this study.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Claire Roddie et al.

Summary: A novel second-generation CD19-CAR therapy (AUT01) has shown promising results in the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL), demonstrating tolerable safety profile, high remission rates, and excellent persistence. This therapy has the potential to become a stand-alone treatment option for r/r adult B-ALL.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Martina Pennisi et al.

Summary: This study found that EASIX and two modified EASIX formulas can predict severe toxicities related to CAR T-cell therapy, with CRP and PLTs being the most significant variables associated with these toxicities. m-EASIX was identified as a critical predictor of disease response and had high discriminatory ability for diagnosing patients with severe CRS and ICANS.

BLOOD ADVANCES (2021)

Add to Collection

Review Hematology

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Juliet Meir et al.

Summary: CAR-T therapy has shown unprecedented response rates in patients with relapsed/refractory hematologic malignancies, but poses distinctive short- and long-term toxicities and infection risks.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article